MC9999 CAR T / Mayo Clinic - LARVOL DELTA

Weaponizing CAR T-cells to attack PD-L1 presenting cells in solid tumors (AACR 2024) - "Collectively, these proof-of-principle study findings substantiate the viability of targeting PD-L1 against both tumors and their immunosuppressive microenvironment. This prototype MC9999 CAR lays the groundwork for further development of clinically applicable CAR T-cell therapy against solid tumors."

CAR T-Cell Therapy • Late-breaking abstract • Brain Cancer • Breast Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1 • PD-L1

Intracranial delivery of MC9999 CAR T-cell therapy: a novel strategy to simultaneously eliminate GBM tumors and immunosuppressive components in the tumor microenvironment (AACR 2025) - "Collectively, the data obtained from this preclinical study support the effectiveness, feasibility and safety of local administration of MC9999 CAR T-cells as a promising new approach for GBM treatment. These encouraging results have motivated us to prepare an Investigational New Drug application to initiate a phase I clinical trial."

Biomarker • CAR T-Cell Therapy • IO biomarker • Tumor microenvironment • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor